AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03561948 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
Study NCT00143819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroskin Forte
Description: Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
Study NCT00143819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Application
Description: Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
Study NCT02014181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: finely ground flaxseed powder
Description: 40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
Study NCT01232673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAC application in Critical Limb Ischemia
Description: Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
Study NCT03415906 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sacubitril+valsartan
Description: Combined angiotensin receptor + neprilysin inhibition
Study NCT03415906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Angiotensin receptor inhibition alone
Study NCT00978900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube
Study NCT00978900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT01835678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: orally 5 mg/d for 4 weeks
Study NCT01835678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once a day for 4 weeks
Study NCT01581957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific Enteral Nutrition
Description: Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
Study NCT01581957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
Study NCT05720572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antazoline
Description: Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Study NCT05720572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Study NCT02794909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary ultrasound exam
Description: The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
Study NCT00986856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucidin® cream
Study NCT00986856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fucidin® cream
Study NCT04336917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic
Description: Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
Study NCT02180100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terconazole Vaginal Suppository
Description: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
Study NCT02180100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
Study NCT00962442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 300 mg/kg for 14 days, intravenously
Study NCT00962442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Glucosé 5% perfusion for 14 days, intravenously
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone
Description: 20 mg p.o. 1 h before the start of anesthesia
Study NCT00681174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: * Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper.
Study NCT00681174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: * Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper.
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: * Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: * Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: * 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: * 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none
Study NCT00681174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none
Study NCT02985099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Rosuvastatin gel
Description: SRP followed by 1.2% Rosuvastatin placement into intrabony defect
Study NCT02985099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus placebo gel
Description: SRP followed by placebo gel placement into intrabony defect
Study NCT03848689 — intervention group
Intervention type: OTHER
Intervention: fluoroquinolone preprescription authorization
Description: Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
Study NCT03848689 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Does not require authorization from Infection Control prior to prescribing fluoroquinolone
Study NCT03459118 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Function Focused Care
Description: The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
Study NCT03459118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function Focused Care
Description: The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
Study NCT00625495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Intravenous infusion over 3 minutes
Study NCT00625495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Oral
Study NCT01622192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florida Probe automated probe
Description: Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
Study NCT03636620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization
Study NCT03636620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization
Study NCT03636620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation/microwave ablation
Description: radiofrequency ablation/microwave ablation
Study NCT02841202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pills
Study NCT02389751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02389751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Given IV
Study NCT02389751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02389751 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04290338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI
Description: Intraoral and extraoral stimulation.
Study NCT00804570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2196044
Description: 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Study NCT00804570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily, orally, 16 weeks
Study NCT00487136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
Study NCT00487136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus ABT-335 plus rosuvastatin 5 mg
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
Study NCT00487136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus ABT-335 plus rosuvastatin 20 mg
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
Study NCT00838292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fortified blended flour - Insta Foundation Plus (with whey protein concentrate)
Description: 300 grams/day for 6 months
Study NCT00838292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling
Study NCT00907751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
Study NCT01129830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dehydroepiandrosterone
Description: DHEA supplementation 25 mg tid for 3 months
Study NCT02042651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shockwave therapy
Description: Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
Study NCT02042651 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low intensity extracorporeal shockwave therapy
Description: Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
Study NCT01799187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
Study NCT01799187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: apexification
Description: apexification uses calcium hydroxide as root medication
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 Placebo
Description: Placebo matching BI 671800
Study NCT01092143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 671800 Placebo
Description: Placebo matching BI 671800
Study NCT02801136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Study NCT02801136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Study NCT03978221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-extubation TDI
Description: A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
Study NCT01529099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGMA HP PARTIAL KNEE
Description: SIGMA HP PARTIAL KNEE
Study NCT02524548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
Study NCT00749476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor IX recovery
Study NCT01687140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Study NCT01687140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Study NCT04541979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aerosolized DNase
Description: DNase
Study NCT04541979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0.9%, isotonic saline
Study NCT03505047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper Intrauterine device
Description: Immediate insertion of the copper intrauterine device after completion of abortion
Study NCT01655420 — intervention group
Intervention type: PROCEDURE
Intervention: LASIK
Description: Laser eye surgery
Study NCT04162184 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention
Description: a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
Study NCT01230281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black bean seed coat extract
Description: 1000 mg oral daily dose for 2 weeks
Study NCT00940381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
Study NCT00940381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
Study NCT02431897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens Cream
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
Study NCT02431897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
Study NCT03624933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Behavioral Coaching Session
Description: The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.